Yes, acid reflux and heartburn show up more often in people taking a GLP-1, though for most people it's a mild, manageable side effect and not a reason to quit. In the clinical trials behind the two most common weight loss medications, reflux was reported by roughly 4% to 5% of people on the drug compared with 2% to 3% on placebo, and a large 2025 study in people with type 2 diabetes found a modest increase in new reflux diagnoses.
If you're on one of these medications, or thinking about starting, and you've noticed a burning feeling after meals or a lot more burping than usual, you're not imagining it.
The Quick Answer
GLP-1 medications slow how fast your stomach empties, which can push stomach contents back toward the esophagus and cause heartburn, burping, and indigestion. In the weight loss trials, gastroesophageal reflux disease (GERD) was reported by 5% of people on semaglutide 2.4 mg versus 3% on placebo, and by 4% to 5% of people on tirzepatide versus 2% on placebo.12 A 2025 cohort study of 24,708 adults with type 2 diabetes found GLP-1 users had a 27% higher relative risk of a new GERD diagnosis than people taking a different diabetes drug.3 Research suggests the effect is real but modest, and smaller meals, slower eating, and a conversation with your prescriber may support relief.
Why a GLP-1 Can Cause Reflux
GLP-1 medications work partly by telling your brain you're full, and partly by slowing gastric emptying, which is the speed at which food leaves your stomach. That second effect is a big reason people feel satisfied on small portions. It also means food sits in the stomach longer, so there's more time and more volume available to wash back up past the valve at the bottom of the esophagus.
That mechanism fits what people report. Heartburn, a sour taste, and burping that smells like what you just ate tend to show up after meals, especially large or fatty ones, and they often cluster around the weeks when the dose is going up and your stomach is still adjusting. The labels for both drugs list burping (eructation) and indigestion (dyspepsia) alongside reflux for exactly this reason, and a lot of people notice the burping first.12
What the Trials and Labels Report
The prescribing information for each drug lists the side effects that were more common on the medication than on placebo in the weight loss trials. Here are the stomach-related ones side by side:
| Side effect | Semaglutide 2.4 mg | Placebo | Tirzepatide (5 / 10 / 15 mg) | Placebo |
|---|---|---|---|---|
| Gastroesophageal reflux disease | 5% | 3% | 4% / 4% / 5% | 2% |
| Dyspepsia (indigestion) | 9% | 3% | 9% / 9% / 10% | 4% |
| Eructation (burping) | 7% | under 1% | 4% / 5% / 5% | 1% |
| Abdominal pain | 20% | 10% | 9% / 9% / 10% | 5% |
Sources: the semaglutide 2.4 mg and tirzepatide prescribing information.12
These came from separate trials with different populations, designs, and ways of grouping symptoms, so the two columns can't be used to say one medication causes more reflux than the other. And the reflux numbers are small in absolute terms: in the semaglutide trials, about 2 more people per 100 reported GERD than on placebo. Burping and indigestion were the more noticeable differences.
What a 2025 Diabetes Study Added
Trial data tells you what people reported over a year or two. A bigger question is whether GLP-1s lead to actual reflux disease over time, and a 2025 study in the Annals of Internal Medicine tried to answer it. Researchers using UK primary care records followed 24,708 adults with type 2 diabetes who started a GLP-1, and compared them with 89,096 who started an SGLT-2 inhibitor, a diabetes drug that doesn't slow stomach emptying. People with prior reflux were excluded, and the median follow-up was three years.3
According to the published summary, GLP-1 users had a risk ratio of 1.27 (95% CI 1.14 to 1.42) for a new GERD diagnosis, which works out to roughly 0.7 extra cases per 100 patients over three years. Complications like erosive esophagitis, strictures, or Barrett esophagus were also more common, with a risk ratio of 1.55 (95% CI 1.12 to 2.29), but the absolute difference was small: about 0.8 per 1,000 patients.3
The study has limits. Everyone in it had type 2 diabetes, so it doesn't directly tell us what happens in people using these drugs for weight loss alone, and the authors noted that diet and lifestyle factors they couldn't measure may have influenced the results. Still, the direction matches the trials and the mechanism, and the authors suggested clinicians stay alert to reflux symptoms when someone starts a GLP-1 so that GERD can be treated early.3
What May Help
Most of what helps is about reducing how much your stomach has to deal with at one time, and none of it requires giving up the medication. These are general strategies commonly used for reflux, and they fit well with how people already eat on a GLP-1:
Eat smaller portions, and stop at the first sign of fullness. Because your stomach empties more slowly, a meal that felt fine before starting may now sit heavy. Slowing down matters as much as shrinking the plate, since fullness takes a while to register. Fatty, fried, and very large meals tend to be the usual culprits, along with alcohol, carbonated drinks, and late-night eating. Leaving two to three hours between your last meal and lying down gives gravity a chance to help, and raising the head of your bed can make a difference for nighttime symptoms. Our guide on what to eat on a GLP-1 covers protein-first meals that tend to be gentler on the stomach.
Keep a short log for a couple of weeks. Noting what you ate, when you took your injection, and when symptoms hit helps you and your provider spot patterns, such as symptoms that peak right after a dose change. If reflux lines up with a dose step, that's useful information, and it's the prescriber's call whether to adjust the plan. Please don't change your dose on your own.
Ask before reaching for over-the-counter acid reducers. Antacids and acid-reducing medications are common and often fine, but whether one is right for you depends on your other medications, your history, and how long you'd need it. A quick check with your provider or pharmacist is the right move, particularly if you find yourself needing something every day.
If you're also dealing with nausea or constipation, those can feed into each other. We cover them in how to manage GLP-1 side effects and GLP-1 constipation.
When Reflux Needs a Phone Call
Occasional heartburn is one thing. A few symptoms mean you should contact your provider promptly instead of managing it at home:
- Trouble swallowing, or food feeling stuck
- Repeated vomiting, or being unable to keep fluids down
- Severe or persistent upper abdominal pain, especially if it spreads to your back
- Black, tarry stools, or vomiting blood
- Heartburn that's daily, wakes you at night, or doesn't respond to the changes above
Chest pain, pressure, or shortness of breath can look like reflux and can be something else entirely. Treat those as an emergency and call 911.
Both labels also warn that severe gastrointestinal reactions can occur, and the tirzepatide label says it isn't recommended for people with severe gastroparesis.2 If you already have significant reflux, a history of GERD, or a stomach-emptying condition, tell your provider before you start so the plan can account for it.
Reflux, Surgery, and Anesthesia
The same slowed stomach emptying is why your anesthesia team cares what you take. The semaglutide and tirzepatide labels both note rare post-marketing reports of pulmonary aspiration (stomach contents entering the lungs) in people on GLP-1s undergoing general anesthesia or deep sedation, and the semaglutide label says some of those patients still had food in the stomach despite following fasting instructions.12
In October 2024, five medical societies, including the American Society of Anesthesiologists and the American Gastroenterological Association, issued joint guidance. It says most patients can continue their GLP-1 before elective surgery, while people at higher risk, such as those still in the early dose-escalation phase or having active nausea, vomiting, or constipation, may be asked to follow a liquid-only diet for 24 hours beforehand or have their procedure timed differently.4 Tell every surgeon, endoscopist, and anesthesiologist that you take a GLP-1 well before the procedure, and follow the plan they give you. Don't stop the medication on your own.
What This Looks Like in Our Lisle Program
Defiant's medical weight loss program is based at 5100 Lincoln Ave in Lisle, and we see patients from Naperville, Downers Grove, Wheaton, and Oak Brook. Programs start from $295 a month and include the medication, provider oversight, bi-weekly titration check-ins, monthly Styku body composition scans, and ongoing nurse access. Bi-weekly check-ins give us a regular chance to hear about reflux or burping while it's still mild, so you aren't left to figure it out between appointments.
If you're curious how the whole program works, see our weight loss page, or read about what a first medical weight loss consultation involves.
- In the weight loss trials, GERD was reported by 5% on semaglutide 2.4 mg vs 3% on placebo, and 4% to 5% on tirzepatide vs 2% on placebo.
- Burping and indigestion showed larger gaps than reflux itself, and the two drugs' trial numbers can't be compared head to head.
- A 2025 study of 24,708 adults with type 2 diabetes found a 27% higher relative risk of a new GERD diagnosis on a GLP-1 (about 0.7 extra cases per 100 patients over three years).
- Smaller meals, eating slowly, avoiding late meals, and tracking symptoms against dose changes may support relief. Dose decisions belong to your prescriber.
- Trouble swallowing, repeated vomiting, black stools, or severe abdominal pain need a prompt call. Chest pain is an emergency.
- Tell your surgical and anesthesia teams you take a GLP-1 before any procedure.
Frequently Asked Questions
Weight Loss That Fits Your Stomach.
If you're considering a GLP-1 and reflux is a worry, bring it up at your consultation. We'll review your history and build a plan with check-ins every two weeks at our Lisle clinic.
Keep Reading
Last updated October 17, 2026.
References
- Semaglutide 2.4 mg injection prescribing information. Table 3 (adverse reactions, weight management trials) and Section 5.10 (pulmonary aspiration). Prescribing information
- Tirzepatide prescribing information. Adverse reactions table (pooled weight reduction trials), Sections 5.2 and 5.9. Prescribing information
- Noh Y, Yin H, Yu OHY, et al. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2025;178(9):1268-1278. PubMed
- American Society of Anesthesiologists. New multisociety clinical practice guidance on GLP-1 receptor agonists in the perioperative period. October 29, 2024. ASA